https://scholars.lib.ntu.edu.tw/handle/123456789/462423
標題: | Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma | 作者: | Chen S.-T. YUNG-MING JENG Chang C.-C. HSIU-HAO CHANG MIN-CHUAN HUANG Juan H.-F. Hsu C.-H. Lee H. Liao Y.-F. Lee Y.-L. WEN-MING HSU HSUEH-FEN JUAN |
公開日期: | 2011 | 卷: | 102 | 期: | 12 | 起(迄)頁: | 2191-2198 | 來源出版物: | Cancer Science | 摘要: | Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported to enhance proliferation and invasion in various cancers. The role of IMP3 on neuroblastoma (NB) is unknown. We aimed to clarify the prognostic significance of IMP3 expression in patients with NB. By microarray analysis, high IMP3 expression was found in patients with poor outcome. IMP3 expression in 90 NB samples was analyzed by immunohistochemical staining to correlate with clinical stages, histology, and patient outcome. Positive IMP3 expression was detected in 52 of 90 patients, and was significantly correlated with undifferentiated histology, advanced stages, MYCN amplification, and poor outcome. In subgroups, positive IMP3 expression could predict an even worse prognosis in patients with advanced disease, with normal MYCN status, or with MYCN amplification (P=0.005, P=0.001, and P=0.033, respectively). The IMP3 expression decreased by induction of differentiation with retinoid acid treatment in SK-N-DZ and SK-N-SH cells in vitro. The invasion ability of NB cells also decreased as IMP3 knockdown by using RNA interference in vitro. In summary, high expression of IMP3 in NB might contribute to the undifferentiated phenotype and invasive behaviors, leading to a poor prognosis. Determining IMP3 expression in NB could help to improve a personalized therapy. ? 2011 Japanese Cancer Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-81855222056&doi=10.1111%2fj.1349-7006.2011.02100.x&partnerID=40&md5=89154f8eaa15410b14bfdb3dd2682e14 https://scholars.lib.ntu.edu.tw/handle/123456789/462423 |
ISSN: | 1347-9032 | DOI: | 10.1111/j.1349-7006.2011.02100.x | SDG/關鍵字: | beta actin; gelatinase B; matrix metalloproteinase 14; mRNA binding protein 3; neuron specific enolase; retinoic acid; RNA binding protein; somatomedin B; tissue inhibitor of metalloproteinase 3; tissue inhibitor of metalloproteinase 4; unclassified drug; advanced cancer; article; cancer invasion; cancer patient; cancer staging; cell proliferation; child; controlled study; female; gene amplification; histology; human; human cell; human tissue; immunohistochemistry; in vitro study; major clinical study; male; microarray analysis; neuroblastoma; oncogene myc; outcome assessment; phenotype; priority journal; prognosis; protein expression; RNA interference; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; Neoplasm Invasiveness; Neoplasm Proteins; Neuroblastoma; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Oncogene Proteins; Prognosis; RNA Interference; RNA, Messenger; RNA, Small Interfering; RNA-Binding Proteins; Tretinoin; Tumor Markers, Biological |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。